As reported in previous sections of the present paper, calcitonin is the standard of care in the diagnosis and monitoring of MTC, while serum ProCT is a potential alternative or at least complementary test to calcitonin in unclear cases being free from analytical limitations and interferences that may lead to false-positive or negative calcitonin results. The gene discussed is CALCA; the disease is medullary thyroid gland carcinoma.